Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Article Details

Authors
Hae-Jin Suh Oh MD, Ángeles Flórez Menéndez PhD, Víctor Sacristán Santos MD, Francisca Fernández Ribeiro PharmD, Lucía Vilanova-Trillo DNP, Manuel Constenla Figueiras PhD, Manuel Pereiro Ferreiros PhD

Article Type
Original Research

DOI
10.7573/dic.2020-6-6

Related Articles

Article Page

Abstract

Background: Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its negative impact on QoL and improve patient outcomes. This study evaluates the impact of CAEs on QoL in outpatients receiving anticancer drugs and aims to determine the differences in QoL between conventional chemotherapy versus targeted therapies.

Methods: A total of 114 cancer patients with CAEs were included in this observational, cross-sectional study. Patient-reported outcomes instruments (Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16) were used.

Results: Mean scores in QoL indices were 65.3±13.4, 8.4±5, and 30.8±16.9 in Functional Assessment of Cancer Therapy – General, Dermatology Life Quality Index, and Skindex-16, respectively. The CAEs that had the greatest impact on dermatologic-related QoL were hand–foot skin reaction, rash, palmo-plantar erythrodysesthesia, and papulopustular eruption. No significant differences in QoL indices according to the type of treatment (conventional chemotherapy versus targeted therapy) were observed.

Conclusions: CAEs, and particularly hand–foot toxicities, rashes, and papulopustular eruptions, can have an impact on QoL in outpatients receiving anticancer drugs as evaluated with three different patient-reported outcomes instruments. No differences in QoL related to CAEs were observed between conventional chemotherapy and targeted therapy.

Keywords: cutaneous adverse events, patient-reported outcomes, quality of life, targeted therapies.

Citation: Suh Oh HJ, Flórez Menéndez A, Sacristán Santos V, Fernández Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, Pereiro Ferreiros M. Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study. Drugs in Context 2020; 9: 2020-6-6. DOI: 10.7573/dic.2020-6-6

Ethics approval and consent to participate: This study was conducted in accordance with the ICH Harmonised Tripartite Guideline as well as according to current national regulations and the ethical principles for medical research of the Declaration of Helsinki. The confidentiality of the data of the subjects participating in the study is guaranteed, ensuring compliance with Spanish Organic Law 15/1999, of December 13, on the Protection of Personal Data. The present study was remitted to the Clinical Research Ethics Committee (Research Ethics Committee of Pontevedra-Vigo-Ourense) for evaluation and subsequent approval before its publication.

Consent for publication: Informed consent was obtained from study participants before performing any study procedure. The researchers informed the patients about all the relevant aspects of the study so that they could decide whether or not to participate in it. Patients had enough time to read the information sheet as well as the opportunity to ask any questions about the study.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. A prepublication version of this manuscript was originally uploaded onto Research Square (doi:10.21203/ rs.2.22831/v1).

Contributions: All authors contributed equally to the preparation of this review and should be considered as first authors. All authors contributed in patient recruitment and data collection. Hae Jin Suh Oh and Ángeles Flórez Menéndez also evaluated CAEs severity and delivered specific treatment recommendations. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/07/dic.2020-6-6-COI.pdf

Acknowledgements: Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain).

Funding declaration: This study was developed as part of an initiative of the research team. Researchers did not receive any compensation for their participation in the study.

Copyright: Copyright © 2020 Suh Oh HJ, Flórez Menéndez A, Sacristán Santos V, Fernández Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, Pereiro Ferreiros M. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Suh Oh HJ, Flórez Menéndez A, Sacristán Santos V, Fernández Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, Pereiro Ferreiros M. https://doi.org/10.7573/dic.2020-6-6. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/cutaneous-adverse-events-and-quality-of-life-in-outpatients-receiving-anticancer-agents:-results-from-an-observational,-cross-sectional-study

Correspondence: Hae-Jin Suh Oh, Dermatology Department, Pontevedra University Hospital, Simón Bolívar s/n 36003, Pontevedra, Spain. suhhaejin@gmail.com, hae.jin.suh.oh@sergas.es

Provenance: submitted; externally peer reviewed.

Submitted: 22 June 2020; Peer review comments to author: 1 July 2020; Revised manuscript received: 13 July 2020; Accepted: 13 July 2020; Publication date: 5 August 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF